Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Joint Venture, Subsidiary

Established: 1997-04-16

Employees: -

Market Cap: -

Website: http://www.cttq.com

Clinical Trials

A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics

Phase 1

Conditions: Advanced Cancer

Interventions: Drug: TQ-B3234

First Posted Date: 2016-12-19

Last Posted Date: 2019-05-21

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT02996838

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics

Phase 1

Conditions: Advanced Cancer

Interventions: Drug: TQ-B3395

First Posted Date: 2016-10-26

Last Posted Date: 2017-09-18

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 35

Registration Number: NCT02944864

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A

Phase 3

Conditions: Hemophilia A

Interventions: Drug: Recombinant Factor VIII (50 IU/kg)
Drug: Recombinant Factor VIII (On-demand treatment)

First Posted Date: 2016-10-12

Last Posted Date: 2016-10-12

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT02930317

Locations: 🇨🇳
Anhui provincial hospital, Hefei, Anhui, China
🇨🇳
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳
Second hospital of Shanxi Medical University, Taiyuan, Shanxi, China

and more 1 locations

A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Anlotinib

First Posted Date: 2016-07-07

Last Posted Date: 2019-05-22

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 22

Registration Number: NCT02825563

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of Anlotinib in Patients With Hepatocellular Carcinoma

Phase 2

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Anlotinib

First Posted Date: 2016-06-22

Last Posted Date: 2016-09-07

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT02809534

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of AL2846 on Tolerance and Pharmacokinetics

Phase 1

Conditions: Advanced Cancer

Interventions: Drug: AL2846

First Posted Date: 2016-05-20

Last Posted Date: 2019-05-21

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT02779699

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics

Phase 1

Conditions: Cancer

Interventions: Drug: Anlotinib

First Posted Date: 2016-04-27

Last Posted Date: 2017-09-18

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT02752516

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury

Phase 2

Completed

Conditions: Drug-Induced Liver Injury

Interventions: Drug: Magnesium Isoglycyrrhizinate Injection 100mg OD
Drug: Magnesium Isoglycyrrhizinate Injection 200mg OD
Drug: Tiopronin Injection

First Posted Date: 2016-04-12

Last Posted Date: 2016-09-27

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 174

Registration Number: NCT02734966

Locations: 🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Nanjing Pulmonary Hospital, Nanjing, Jiangsu, China

and more 5 locations

A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients

Phase 2

Terminated

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo
Drug: Roflumilast

First Posted Date: 2016-02-02

Last Posted Date: 2019-05-21

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 55

Registration Number: NCT02671942

Locations: 🇨🇳
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

Phase 2

Completed

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Placebo
Drug: Anlotinib

First Posted Date: 2016-01-07

Last Posted Date: 2019-06-05

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 164

Registration Number: NCT02649361

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy